|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-5-4
|
|
pubmed:abstractText |
To evaluate vitreous vascular endothelial growth factor (VEGF), stromal cell-derived factor 1alpha (SDF-1alpha), interleukins (ILs), and tumor necrosis factor-alpha (TNF-alpha) after intravitreal bevacizumab or triamcinolone acetonide (TA) in eyes with proliferative diabetic retinopathy (PDR).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CXCL12,
http://linkedlifedata.com/resource/pubmed/chemical/Glucocorticoids,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukins,
http://linkedlifedata.com/resource/pubmed/chemical/Triamcinolone Acetonide,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/VEGFA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1549-4713
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
116
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
921-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19410951-Adult,
pubmed-meshheading:19410951-Aged,
pubmed-meshheading:19410951-Angiogenesis Inhibitors,
pubmed-meshheading:19410951-Antibodies, Monoclonal,
pubmed-meshheading:19410951-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19410951-Chemokine CXCL12,
pubmed-meshheading:19410951-Diabetic Retinopathy,
pubmed-meshheading:19410951-Down-Regulation,
pubmed-meshheading:19410951-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:19410951-Female,
pubmed-meshheading:19410951-Glucocorticoids,
pubmed-meshheading:19410951-Humans,
pubmed-meshheading:19410951-Injections,
pubmed-meshheading:19410951-Interleukins,
pubmed-meshheading:19410951-Male,
pubmed-meshheading:19410951-Middle Aged,
pubmed-meshheading:19410951-Retinal Neovascularization,
pubmed-meshheading:19410951-Retrospective Studies,
pubmed-meshheading:19410951-Triamcinolone Acetonide,
pubmed-meshheading:19410951-Tumor Necrosis Factor-alpha,
pubmed-meshheading:19410951-Vascular Endothelial Growth Factor A,
pubmed-meshheading:19410951-Vitrectomy,
pubmed-meshheading:19410951-Vitreous Body
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
|
|
pubmed:affiliation |
Department of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
